Tirzepatide Dosage: Reported Research Ranges
Reported in research: 5–15 mg once weekly (subcutaneous) in published human trials; a practitioner protocol lists 2.5 mg and 8 mg weekly. Sources vary.
Dosing Protocols Research · Peptide dosage chart · What is Tirzepatide? · Research library
Reported ranges by source
| Reported range | Source type | Evidence strength |
|---|---|---|
| 5–15 mg once weekly, subcutaneous (arms of 5, 10 and 15 mg) | Human trial (published study) | Human: randomized controlled trials |
| 2.5 mg weekly and 8 mg weekly (both listed by one source) | Practitioner protocols | Practitioner protocol (not a clinical trial) |
Amounts are shown as each source reports them. Where sources disagree, the table lists each one; there is no single agreed amount.
Published human trials in our library
- Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA · PubMed 42675225
- Tirzepatide monotherapy in Chinese patients with early type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial (SURPASS-CN-MONO) · PubMed 42296968
- Short-Term Combined Treatment With Tirzepatide and Metformin for Overweight/Obese Chinese Women With Polycystic Ovary Syndrome: A Prospective, Open-Label, Randomised Controlled Trial · PubMed 42236268
- Effect of Tirzepatide on Health-Related Quality of Life in Japanese Patients With Obesity Disease: Patient-Reported Outcomes From the SURMOUNT-J Study · PubMed 42108080
- Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1 · PubMed 42082865
- Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial · PubMed 41419618
- Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial · PubMed 41198460
- Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide · PubMed 41066427
- Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial · PubMed 41017451
- Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial · PubMed 40975112
- Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis · PubMed 40903131
- Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity · PubMed 40774158
- Indirect comparative efficacy and safety of tirzepatide [amount hidden] versus semaglutide [amount hidden] for the management of obesity and overweight in patients with type 2 diabetes · PubMed 40537987
- Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial · PubMed 40329666
FAQ
What Tirzepatide dosage is reported in research?
Reported in research: 5–15 mg once weekly (subcutaneous) in published human trials; a practitioner protocol lists 2.5 mg and 8 mg weekly. Sources vary.
Is there human-trial evidence for Tirzepatide dosing?
Yes. Published randomized trials in our study library report the amounts in the table above.
Why do the reported Tirzepatide amounts differ?
Each source studied or described a different group, form, goal and time frame, so reported amounts vary between sources. PeptideWhiz lists each one with its source type instead of picking a single amount.
Where can I convert a Tirzepatide amount into syringe units?
The PeptideWhiz calculator for Tirzepatide converts a vial amount, water volume and target amount into mL and syringe units. It does not suggest an amount.
Last updated: November 2, 2026.
Research information only. This page lists amounts as reported in published studies, practitioner protocols and Dr. Trevor reports. It is not medical advice and not a recommendation for any person. Sources vary, and most of these compounds are not approved for the uses discussed.